

## Overview

### Useful For

Detecting septin-5 IgG in spinal fluid (CSF) specimens

Reporting an end titer result from CSF specimens

### Testing Algorithm

If the indirect immunofluorescence pattern suggests septin-5, then septin-5 antibody cell-binding assay and this test will be performed at an additional charge.

### Method Name

Only orderable as a reflex. For more information see MDC2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid.

Indirect Immunofluorescence Assay (IFA)

### NY State Available

Yes

## Specimen

### Specimen Type

CSF

### Specimen Required

Only orderable as a reflex. For more information see MDC2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid.

**Container/Tube:** Sterile vial

**Specimen Volume:** 1.5 mL

### Specimen Minimum Volume

See Specimen Required

### Reject Due To

|                 |        |
|-----------------|--------|
| Gross hemolysis | Reject |
| Gross lipemia   | Reject |

|               |        |
|---------------|--------|
| Gross icterus | Reject |
|---------------|--------|

**Specimen Stability Information**

| Specimen Type | Temperature              | Time     | Special Container |
|---------------|--------------------------|----------|-------------------|
| CSF           | Refrigerated (preferred) | 28 days  |                   |
|               | Frozen                   | 28 days  |                   |
|               | Ambient                  | 72 hours |                   |

**Clinical & Interpretive****Clinical Information**

Septin-5 IgG is a biomarker of a rapidly progressive, but treatable, form of autoimmune cerebellar ataxia. Patients present with subacute onset of cerebellar ataxia with prominent eye movement symptoms (oscillopsia or vertigo). Improvement may occur after immunotherapy.

**Reference Values**

Only orderable as a reflex. For more information see MDC2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid.

<1:2

**Interpretation**

Seropositivity for septin antibodies by indirect immunofluorescence is consistent with a diagnosis of autoimmune disease of the central nervous system. Cell-binding assay testing for septin-5 IgG is required to confirm the diagnosis.

**Cautions**

Negative results for septin antibodies do not exclude neurological autoimmunity or cancer.

**Clinical Reference**

- Honorat JA, Lopez-Chiriboga AS, Kryzer TJ, et al: Autoimmune septin-5 cerebellar ataxia. *Neurol Neuroimmunol Neuroinflamm*. 2018 Jul 9;5(5):e474
- [Honorat JA, Miske R, Scharf M, et al: 416. Neuronal septin autoimmunity: Differentiated serological profiles and clinical findings. \*Ann Neurol\*. 2020 Oct; 88\(Suppl 25\):S55. Abstract](#)

**Performance****Method Description**

The patient's sample is tested by a standardized immunofluorescence assay that uses a composite frozen section of mouse cerebellum, kidney, and gut tissues. After incubation with sample and washing, fluorescein-conjugated goat-antihuman IgG is applied. Neuron-specific autoantibodies are identified by their characteristic fluorescence staining

patterns. Samples that are scored positive for any neuronal nuclear or cytoplasmic autoantibody are titrated to an endpoint. Interference by coexisting non-neuron-specific autoantibodies can usually be eliminated by serologic absorption. (Honorat JA, Komorowski L, Josephs KA, et al: IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. *Neurol Neuroimmunol Neuroinflamm* 2017 Jul 18;4(5):e385. doi: 10.1212/NXI.0000000000000385)

**PDF Report**

No

**Day(s) Performed**

Monday through Sunday

**Report Available**

5 to 10 days

**Specimen Retention Time**

28 days

**Performing Laboratory Location**

Rochester

**Fees & Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

86256

**LOINC® Information**

| Test ID | Test Order Name         | Order LOINC® Value |
|---------|-------------------------|--------------------|
| SP5TC   | Septin-5 IFA Titer, CSF | 101459-6           |

| Result ID | Test Result Name        | Result LOINC® Value |
|-----------|-------------------------|---------------------|
| 616114    | Septin-5 IFA Titer, CSF | 101459-6            |